Trial Profile
MULTICENTER PHASE II STUDY FOR THE EVALUATION OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2012
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BOXE
- 18 Apr 2012 New trial record